{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":4,"sponsored":0,"items":[{"id":"n_qrx2sayyue7lnxo5y23a","seq":1064625,"kind":"article","title":"F. Hoffmann-La Roche Ltd: Roche's giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine","url":"https://www.finanznachrichten.de/nachrichten-2026-10/69724812-f-hoffmann-la-roche-ltd-roche-s-giredestrant-combination-significantly-improved-progression-free-survival-in-er-positive-advanced-breast-cancer-in-p-399.htm","published":"2026-10-01T06:13:31Z","seen":"2026-10-01T06:13:31Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","business","science","health"],"authors":["GlobeNewswire (Europe)"],"entities":[{"id":"Q131882228","name":"F. Hoffmann-La Roche Ltd","type":"org"},{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q582728","name":"The New England Journal of Medicine","type":"org"}],"story":"st_xh67iaelhosqksymdknq","category":"health","category_p":0.73,"sentiment":"positive","tone":-0.13,"political":0.03},{"id":"n_pg5qr6mjtpf7suudsd7a","seq":1101809,"kind":"article","title":"Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine","url":"https://www.timesargus.com/news/business/genentech-s-giredestrant-combination-significantly-improved-progression-free-survival-in-er-positive-advanced-breast-cancer/article_0d093db4-c963-5d31-a594-aa935a3b8e4f.html","summary":"SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 1, 2026--","published":"2026-10-01T05:00:39Z","seen":"2026-10-01T09:49:09Z","lang":"en","country":"US","source":{"id":"kite-timesargus-com-f2ab3d","name":"timesargus.com","domain":"timesargus.com","outlet":{"wikidata":"Q4863287","name":"Barre Montpelier Times Argus","type":"newspaper","country":"US","designations":["newspaper"]}},"via":"kite-timesargus-com-f2ab3d","topics":["vermont"],"authors":["Business Wire"],"entities":[{"id":"Q899140","name":"Genentech","type":"org"},{"id":"Q131198690","name":"Giredestrant","type":"other"},{"id":"Q582728","name":"The New England Journal of Medicine","type":"org"}],"story":"st_xh67iaelhosqksymdknq","category":"science-technology","category_p":0.46,"category2":"health","sentiment":"positive","tone":0.62,"political":0.03},{"id":"n_xh67iaelhosqksymdknq","seq":1059158,"kind":"press_release","title":"Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine","url":"https://www.globenewswire.com/news-release/2026/10/01/3372515/0/en/roche-s-giredestrant-combination-significantly-improved-progression-free-survival-in-er-positive-advanced-breast-cancer-in-phase-iii-evera-data-published-in-the-new-england-journal.html","summary":"Basel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly improved progression-free survival (PFS) versus standard endocrine therapy plus everolimus, were published in The New England Journal of Medicine (NEJM) . The evERA trial is evaluating giredestrant, an investigational oral selective oestrogen receptor degrader…","published":"2026-10-01T05:00:00Z","seen":"2026-10-01T05:24:16Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","swx:ro","otc markets:rhhby","swx:rog","ch0012032113","us7711951043","ch0012032048","9014"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q582728","name":"The New England Journal of Medicine","type":"org"}],"mentions":2,"story":"st_xh67iaelhosqksymdknq","category":"health","category_p":0.83,"sentiment":"positive","tone":0.62,"political":0.04},{"id":"n_zmkokvaqpaupnpavknua","seq":845232,"kind":"article","title":"세브란스 심장내과, 9개월간 'NEJM' 논문 4편 게재","title_en":"Severance Cardiology, 4 papers published in 'NEJM' over 9 months","url":"https://www.medipana.com/news/articleView.html?idxno=418505","summary":"세브란스 심장혈관병원 심장내과 교수진이 9개월여 동안 국제학술지 \\'New England Journal of Medicine(NEJM)\\'에 연구 논문 4편을 잇따라 게재했다. 연구 주제는 심방세동 환자의 항응고치료부터 저밀도지단백(LDL) 콜레스테롤 관리, 관상동맥 스텐트 시술 후 항혈소판 치료까지 심혈관질환의 주요 치료전략을 아우른다. 세브란스 심장혈관병원은 심장내과 교수진이 지난해 11월 8일부터 올해 8월 29일까지 총 4편의 논문을 NEJM에 발표했다고 밝혔다. 첫 연구는 지난해 11월 발표된 \\'Therapy for Atria","published":"2026-09-30T06:46:08Z","seen":"2026-09-30T07:25:24Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","학술n비즈"],"authors":["박으뜸 기자"],"entities":[{"id":"Q582728","name":"The New England Journal of Medicine","type":"other"}],"story":"st_5flyahyj5wbmvgjwhsha","category":"health","category_p":0.84,"sentiment":"neutral","tone":0.07,"political":0.06}]}